Abstract
As emicizumab shares no sequence homology with FVIII, in patients with haemophilia A, haemostasis can be restored irrespectively of the presence of factor VIII inhibitors. Emicizumab therefore substantially improves upon current treatment options. This study aims at comparing the patients’ quality of life (QoL) and clinical outcomes of emicizumab prophylaxis therapy and recombinant FVIII (rFVIII) prophylaxis for the treatment of severe Haemophilia A, based on a Markov cohort simulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
